Compare Vanguard Total Bond Market Index Fund ETF (BND) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total Bond Market Index Fund ETF vs Inovio Pharmaceuticals Inc — how do they compare? Vanguard Total Bond Market Index Fund ETF trades at $72.34, while Inovio Pharmaceuticals Inc trades at $0.75 (market cap $78.55M). Which is the better fit depends on your goals.
| BND | INO | |
|---|---|---|
52-Week High | $75.17 | $2.87 |
52-Week Low | $72.15 | $0.66 |
Market Cap | — | $78.55M |
Sector | — | Health |
Enterprise Value | — | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BND trades at $72.36, up 0.29% today, amid a bearish technical outlook with moving averages signaling sell pressure and oscillators neutral. The ETF shows consistent dividend distributions, with recent payouts of $0.25 and $0.24. News highlights institutional activity, including Boston Standard Wealth reducing its stake by 30.6% in Q2 2026 (SEC filing, 2026-08-05), while broader bond ETF inflows reached nearly $300 billion in H1 2026 (Zacks Investment Research, 2026-08-06).
The outlook remains cautious due to technical weakness and interest rate sensitivity, but BND offers income stability through dividends. Risks include Treasury yield volatility and inflation data impacts, yet it serves as a core fixed-income holding for diversification amid market uncertainty.
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
